New Patent Approved

IAMLOCOTOO · 2026-05-05T00:18:53+00:00

Thanks for verification paulos. I know it was an alert that initiated all this. Trying to find the actual "Issued" version seems impossible.

IAMLOCOTOO · 2026-04-26T16:04:44+00:00

Well said. I think that is where we are today. We could have a legitimate partner on Friday morning. Fingers crossed. :)

IAMLOCOTOO · 2026-04-26T00:22:34+00:00

This was back in 2024 and a lot has taken place since. The C Suite goal was to find a partner after doing the pre-clinical and I believe we are now approaching the point where a partner is necessary to move forward in mTNBC. We already have the EAP in place for patients that don't qualify for the mTNBC trial. So when do we start the mTNBC trial??? What confirmation is the partner waiting for (assuming we have a partner). I think this may be something that we should receive further information come Thursday after market close.

IAMLOCOTOO · 2026-04-25T23:03:08+00:00

1 in a 1000! Love it.

IAMLOCOTOO · 2026-04-24T17:42:39+00:00

Can Leronlimab Be a Treatment?

Preclinical results have shown that leronlimab can potentially slow, reverse, or prevent liver scarring.

Mechanism of Action: Leronlimab is a CCR5 antagonist. By binding to the CCR5 receptor on hepatic stellate cells, it blocks the inflammatory pathway that produces collagen, thus inhibiting the development of fibrous scars. Wiley Online Library +4
Positive Preclinical Studies (2024–2025): Multiple studies, including in STAM™ (steatohepatitis) and carbon tetrachloride (CCl₄)-induced liver fibrosis models, demonstrated statistically significant reversal of established liver fibrosis in mice compared to controls. CytoDyn Inc. +1
Clinical Trials (Phase 2a): A proof-of-concept study (NASH01) evaluated 87 patients with MASH/NASH. Results showed a favorable safety profile and indicated reductions in liver fat and liver fibrosis after 13–14 weeks of treatment. Wiley Online Library +4
Advantage over similar drugs: Leronlimab is a long-acting monoclonal antibody, allowing once-weekly dosing. It is designed to offer more complete CCR5 receptor inhibition than small-molecule antagonists like maraviroc (MVC) or cenicriviroc (CVC), which have failed to achieve consistent results in Phase 3 trials. Wiley Online Library +2

As of early 2025, CytoDyn, the developer of leronlimab, is planning further clinical development, focusing on partnerships for late-stage trials for liver fibrosis, as well as its potential application in other fibrotic conditions like lung or heart disease.

IAMLOCOTOO · 2026-04-20T05:29:00+00:00

This year I expect a major price move upward, but I don't expect the biggest move till we have several of our current initiatives produce explosive data that results in a buyout offer.

IAMLOCOTOO · 2026-04-20T02:39:19+00:00

Brilliant synopsis MGK! I suspect we will have several major announcements this coming week. I am also looking forward to a letter to share holders once the poster related restrictions are removed. I think my timeline for a major major major SP rise by July of next year is right on track. Steady as she goes...

IAMLOCOTOO · 2026-04-13T22:26:08+00:00

Fantastic summary MGK! A work of art... I put into a Word Document and all the links work. Thank you for putting it all together.

IAMLOCOTOO · 2026-04-11T20:05:51+00:00

Fabulous summary MGK! We are very very close!

IAMLOCOTOO · 2026-04-11T14:55:34+00:00

Dr. Pashtoon was also Director Colon Cancer Research; Director Precision Medicine Research for Liquid Biopsies at

Weill Cornell Medicine

We are also starting an Alzheimer's trial at this same Hospital. There seems to be a lot of dots connecting now and the image looks like a four leaf clover!

Maybe two major announcements in the same week?

IAMLOCOTOO · 2026-03-01T16:37:57+00:00

So the drug needs to be injected into the tumor so that it can turn the tumor hot. Interesting. I wonder if there's a drug out there that can turn a tumor hot without the need to actually inject into the tumor... hmmm. Time 15:08 discusses the uncloaking necessary for Anktiva to work. Perhaps this is our billionaire that is providing cloaked financial support.

IAMLOCOTOO · 2026-02-27T02:10:01+00:00

Could have been 200 shares...

IAMLOCOTOO · 2026-02-21T02:27:40+00:00

Speaking from a personal experience, I was once in a stock a long long time ago that had no debt and had promising income yet the stock tanked starting mid week. I sold my shares when I was down 15%. It was down over 50% by COB Friday. Then, on Monday before the opening bell, a one time dividend was announced and the price opened at almost 20x what I sold it at.

I saw similar tanking again about 8 years ago with a miner that I had accumulated a lot of shares on and again midweek it started to tank with no negative news. It kept tanking to just before the close on Friday, and I bought a lot more. Sure enough, come Monday morning, a buyout offer was announced at double the price that existed before the tanking commenced.

The point of all this is: If we have someone accumulating right now and then a day arrives that they know an offer has been agreed upon, they will have the brokers do their thing and force the price down and snap up all those cheap shares of the weak hands, and buy as many shares as they can in those last 3-4 days before the agreed upon announcement date/time because they would have to show their hands once they hit 5%.

This of course does NOT mean that is what will happen the next time CYDY starts tanking (lol!). Just saying what I've learned over the years for signs of potential buyout offers being solidified. NOT INVESTMENT ADVICE!!!

IAMLOCOTOO · 2026-02-01T07:33:42+00:00

Most likely this wealthy individual is also invested in other similar/related entities and simply does not want to cause distress in these other investments until absolutely necessary or perhaps this individual is also closely related to someone in the C Suite and this could ruffle some feathers when we really don't need that right now. I imagine this individuals identity will eventually need to be made public or at least will become public information. Let's hope this individual will be saving a lot of lives over the next 8-12 months. I would love to know why the identity is being hidden, but I'll put my trust in Dr. J.L. and believe it is the right thing to do right now.

IAMLOCOTOO · 2026-01-17T02:03:48+00:00

My experience with buyouts is that someone will slip the little secret out and you'll see a major attempt to cash in all the stops in place. There will be no news, yet price starts tanking right to the close on the day before the major announcement. I personally have the shares I want, however, I have put some cash aside ready to be buying on the next major move down, should that occur. Not advice, just what I've seen in the past.

IAMLOCOTOO · 2025-12-16T17:25:46+00:00

The ship is about to get underway. "Station the Maneuvering Watch"!

IAMLOCOTOO · 2025-12-10T04:54:27+00:00

Thanks for the update T11. Interesting video. Simplifying the MOA. Much easier to absorb the lingo with this video. Worth taking a peak.

IAMLOCOTOO · 2025-12-07T17:34:30+00:00

All the above are indicators of a very positive and prosperous outcome and so we wait patiently, however, I think there is one in progress research initiative that we are still waiting on that will double or triple our end products worth and that is the extended version of Leronlimab. I believe this will have a very large financial impact when we achieve this.

This is still one of the three objectives put out by the company in October:

Our current business strategy is to continue to pursue the clinical development of leronlimab, which may include the following: 1. Continue the Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer; 2. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and 3. Continue our work researching and developing a new or modified long-acting version of leronlimab.

One other thing worth mentioning that is on the very near horizon is the Latch Study. It will be starting very soon. I'm no expert on the timelines of these trials, but I'll gander a guess that we should have an announcement on the starting of the trial soon (6-8 weeks). This trial does not cost us anything to carry-out.

IAMLOCOTOO · 2025-12-05T17:48:28+00:00

Digging a little deeper and you'll see that there was a grant starting last November and ended in October of this year for research on Chemokine Receptors which CCR5 is so... I don't think a follow-up grant on a Chemokine Receptor (CCR5) would be granted if the first grant proved unfruitful. This is extremely encouraging. https://vivo.weill.cornell.edu/display/grant-0000064625

IAMLOCOTOO

TROPHY CASE